Abstract Body

Two serologic assays, the BioPlex 2200 HIV Ag-Ab screening assay (BPC) that detects and differentiates p24 antigen (Ag) and HIV-1 and HIV-2 antibodies (Ab) and the GeeniusTM HIV-1/2 supplemental assay (Geenius) that differentiates HIV-1 from HIV-2 Ab, were approved after the 2014 CDC/APHL laboratory HIV diagnostic algorithm was released. We evaluated the performance of these assays in HIV-1 seroconverters (SC) and HIV-2 infections in the context of the diagnostic algorithm.

501 sequential plasma specimens (134 collected during antiretroviral therapy (ART)) from 49 U.S. HIV-1 SC and plasma from 100 HIV-2 Ab-positive persons (16 from the U.S. and 84 from Ivory Coast (IVC)) were tested with BPC and Geenius. Nucleic acid testing (NAT) was done with APTIMA HIV-1 RNA qualitative assay in 497 SC samples and with the Roche COBAS AmpliPrep/TaqMan HIV-1 v2.0 test in four. The algorithm was evaluated individually for each SC collection time.

In SC, BPC was non-reactive (NR) in 91 samples, 67 of which were collected before the first NAT-reactive (R) and 24 were NAT-only R. After the first NAT-R, 407/434 (93.8%) were BPC-R and 27 were BPC-NR including four in a secondary negative diagnostic phase in three SC. Of 407 BPC-R, 315 (77.4%) were Geenius HIV-1-positive, 31 (7.6%) HIV-1-indeterminate, and 61 (15%) HIV-negative. All 41 BPC Ag-only R samples were Geenius HIV-negative. APTIMA resolved 88/92 (95.7%) Geenius HIV-negative or HIV-1-indeterminate samples. Overall, the algorithm detected 92.9% of early HIV-1 infections including 99.3% of samples during ART. Among 100 HIV-2 samples, 95 were BPC HIV-2 Ab-R (16 U.S., 79 IVC) and five from IVC were HIV-1/HIV-2 Ab-undifferentiated. Of 95 BPC HIV-2 Ab-R samples, 81 were Geenius HIV-2 positive (including 46 with HIV-1 cross-reactivity), 2 repeatedly HIV-2 indeterminate (gp36 reactivity only), 9 HIV untypable, 1 HIV indeterminate and 2 repeatedly HIV negative. Of 5 BPC HIV-2 undifferentiated from IVC, all were Geenius HIV-2 positive.

BPC performed well and detected Ag in early HIV-1 infections, but rarely a second negative diagnostic phase was observed. In the algorithm, BPC Ag-only R samples could be confirmed directly with NAT. BPC differentiated HIV-1 from HIV-2 Ab in most samples, but in combination with Geenius results, the possible final interpretations increased. These results provide important data for potential updates to the CDC/APHL recommendations for HIV diagnostics.